Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis

Official title

A Randomized Controlled Trial on Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis

Overview

This is a single-center, double-blind, randomized controlled study. The patients were divided into control group and experimental group, 80 cases each. From the first day of radiotherapy to the end of radiotherapy, the experimental group was treated with 24 grams of taurine granule (containing 4.8 grams of taurine) before each day's radiotherapy. The control group was treated with the same amount of placebo.

Detailed description

Implementation of double-blind:

Doctors, patients and clinical research coordinator (CRC) are blind. The medicine will be encoded before the beginning of the trial, and will be administered before each radiotherapy session. After the patient take the medication, the CRC takes the patient to the treatment room for radiotherapy.

Interventions

• Drug Taurine granule
  24 grams of taurine granule + 2 Gray radiation dose each time.
• Drug Placebo granule
  24 grams of placebo granule + 2 Gray radiation dose each time.

Primary outcome measures

• Incidence rate and severity of acute radiation-induced oral mucositis [Time frame: The first day, the second, third, fourth, fifth, sixth week during radiotherapy; the 7±1 day, the 14±2 day, the 21±3 day, the 28±5 day after the last day of radiotherapy (follow-up); 3 month±5 days after the last day of radiotherapy (study endpoint).]

Secondary outcome measures (2)

• Incidence rate and severity of acute radiodermatitis [Time frame: The first day, the second, third, fourth, fifth, sixth week during radiotherapy; the 7±1 day, the 14±2 day, the 21±3 day, the 28±5 day after the last day of radiotherapy (follow-up); 3 month±5 days after the last day of radiotherapy (study endpoint).]
• Safety physiological parameters [Time frame: Clinical symptoms and adverse events are recorded when occured. Blood routine and blood biochemistry examination are evaluated during screening, after 2/4/6 weeks of radiotherapy and 4 weeks after the last day of radiotherapy.]

Eligibility criteria

Inclusion criteria

• Patients voluntarily joined the study, were informed of the purpose and process of the study, signed the informed consent form, and were willing and able to abide by the study protocol.
• Aged 18 to 80, with no gender restrictions.
• Patients that require radiotherapy after surgery for oral/oropharyngeal cancer. After evaluation by the radiation oncologist, radiotherapy at 30 sessions /60Gy is planned.
• The expected survival period is more than 6 months.
• No radiotherapy for the head and neck has been performed in the past, and no other medications that affect the results of this trial have been used. No chemotherapy or immunotherapy was performed within one month before the beginning of the trial.

Exclusion criteria

• Uncontrollable local or systemic infections of the oral cavity and head and neck.
• Active or history of autoimmune diseases; Diseases requiring systemic steroid hormones or immunosuppressive medications.
• Bleeding occurred within 3 months before enrollment, including but not limited to: gastrointestinal bleeding caused by gastric fundus or esophageal varices, increased risk of bleeding caused by portal hypertension, active gastrointestinal bleeding, etc. Or there is a risk of major bleeding as assessed by the researcher.
• Arterial/venous thrombosis that occurred within 6 months prior to the screening, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, etc.
• Interstitial pneumonia or active pneumonia with clinical significance, or other respiratory diseases that seriously affect lung function.
• History of cardiovascular diseases, including but not limited to: (1) Congestive heart failure (NYHA grade > 2); (2) Unstable angina pectoris; (3) Myocardial infarction occurred in the past three months; (4) Any supraventricular arrhythmia or ventricular arrhythmia that requires treatment or intervention.
• Severe endocrine or hematopoietic system diseases (such as diabetes, leukemia, etc.), gastrointestinal obstruction, active bleeding, gastric perforation and other conditions.
• Combined with malignant tumors of other organs.
• Intractable or refractory epilepsy, with a large amount of pleural effusion, ascites, pericardial effusion, etc. that cannot be controlled by medicines.
• History of HIV, syphilis, active hepatitis, active pulmonary tuberculosis, active EBV and/or CMV infection within one year before screening, or those with a history of active pulmonary tuberculosis infection for more than one year without regular treatment; active hepatitis B or C. Patients with positive HBsAg or HBcAb can participate in this study if the HBV DNA test is below the lower limit of the normal value detected by the research center; patients with positive HCV antibody can participate in this study if the HCV RNA test is below the lower limit of the normal value detected by the research center.
• History of allogeneic bone marrow transplantation or solid organ transplantation.
• Have received cell therapy products that have undergone genetic modification or editing in the past.
• Have previously used medicines that can cause medication-related osteonecrosis of the jaw.
• Have taken drugs containing taurine within one month before randomization in this study.
• Allergic to taurine.
• Patients who, in addition to radiotherapy, requires chemotherapy or immunotherapy simultaneously.
• Mental illness, alcohol abuser, drug user or drug abuser.
• Pregnant or lactating women; Women who plans to become pregnant within half a year after treatment.
• Poor compliance or other circumstances assessed by the researcher as unsuitable for participation in this clinical study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Prevention

Study locations

China · 1 center

• Shanghai ninth people's hospital — Shanghai

Identifiers

NCT: NCT07029178 · JYKQ-2025-001

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗